Rayno Life Science Movers -Diagnostics Review Next Week
Despite some choppiness in biotech trading this week many of our stocks did well. I won't go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my "bubble" article. There is also a lot of focus in the media about soaring biotech stocks with IBB at $272 just shy of 52 week high of $275.
Here are some Rayno Life Science stocks of note this week. Review the complete list on the Raygent WEB site as many stocks are at new highs.
Albany Molecular, (AMRI $16) nobody liked this biotech contract services (CRO) stock when we recommended it at $4.68 at a 0.55 P/S less than two years ago. Now the P/S is still only 2. Guidance and 2013 results pleased investors today.
Cubist, (CBST $81.23) new highs and acceptance of EMA marketing authorization for Tedizolid. Price to Sales only 5.72.
Illumina, (ILMN $178) momentum stock with news on sequencing app for Downs Syndrome.
Roche Holdings, (OTCQX:RHHBY $38.50) 2:1 split and new high. Leader in diagnostics and biopharmaceuticals
ThermoFisher (TMO $124.91) at new highs and recently upgraded.
XLV ($59.44) a healthcare EFT has rallied from the January bottom and is now up 7.2% YTD.
New picks since last December are all doing well: Nanostring Technologies (NASDAQ:NSTG), Roche Holdings (RHBBY) and XLV a healthcare ETF.
Large caps hit new highs recently: ALXN AMGN, BIIB, GILD. Watch the technicals particularly the volatile ETF XBI which holds more of the mid and small caps.
Our core position Fidelity Select Biotech Find (FBIOX $228.44) is up 25.7% YTD.
As most 2013 earnings reports are in we will review all Rayno Tools and Diagnostics stocks next week.
Disclosure: I am long RHHBY.
Additional disclosure: I am long Fidelity Select Biotech Fund (MUTF:FBIOX)